Loading…

Type II Endometrial Cancer Overexpresses NILCO: A Preliminary Evaluation

Objective. The expression of NILCO molecules (Notch, IL-1, and leptin crosstalk outcome) and the association with obesity were investigated in types I and II endometrial cancer (EmCa). Additionally, the involvement of NILCO in leptin-induced invasiveness of EmCa cells was investigated. Methods. The...

Full description

Saved in:
Bibliographic Details
Published in:Disease markers 2017-01, Vol.2017 (2017), p.1-14
Main Authors: Gonzalez-Perez, Ruben Rene, Pattillo, Roland, Candelaria, Pierre V., Lee, Regina, Lanier, Viola, Vann, Kiara T., Oprea-Ilies, Gabriela, Daley-Brown, Danielle, Quarshie, Alexander
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c499t-240be7b9b42295518241224551f4247edfe226a5393b4ce4d50843f7b74ae7eb3
cites cdi_FETCH-LOGICAL-c499t-240be7b9b42295518241224551f4247edfe226a5393b4ce4d50843f7b74ae7eb3
container_end_page 14
container_issue 2017
container_start_page 1
container_title Disease markers
container_volume 2017
creator Gonzalez-Perez, Ruben Rene
Pattillo, Roland
Candelaria, Pierre V.
Lee, Regina
Lanier, Viola
Vann, Kiara T.
Oprea-Ilies, Gabriela
Daley-Brown, Danielle
Quarshie, Alexander
description Objective. The expression of NILCO molecules (Notch, IL-1, and leptin crosstalk outcome) and the association with obesity were investigated in types I and II endometrial cancer (EmCa). Additionally, the involvement of NILCO in leptin-induced invasiveness of EmCa cells was investigated. Methods. The expression of NILCO mRNAs and proteins were analyzed in EmCa from African-American n=29 and Chinese patients (tissue array, n=120 cases). The role of NILCO in leptin-induced invasion of Ishikawa and An3ca EmCa cells was investigated using Notch, IL-1, and leptin signaling inhibitors. Results. NILCO molecules were expressed higher in type II EmCa, regardless of ethnic background or obesity status of patients. NILCO proteins were mainly localized in the cellular membrane and cytoplasm of type II EmCa. Additionally, EmCa from obese African-American patients showed higher levels of NILCO molecules than EmCa from lean patients. Notably, leptin-induced EmCa cell invasion was abrogated by NILCO inhibitors. Conclusion. Type II EmCa expressed higher NILCO molecules, which may suggest it is involved in the progression of the more aggressive EmCa phenotype. Obesity was associated with higher expression of NILCO molecules in EmCa. Leptin-induced cell invasion was dependent on NILCO. Hence, NILCO might be involved in tumor progression and could represent a new target/biomarker for type II EmCa.
doi_str_mv 10.1155/2017/8248175
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5474242</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A550015085</galeid><sourcerecordid>A550015085</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-240be7b9b42295518241224551f4247edfe226a5393b4ce4d50843f7b74ae7eb3</originalsourceid><addsrcrecordid>eNqNkcFP2zAUxq2JCTrgtvMUicukLWA7dmzvMKmqOqhU0R3Y2XKSFzBK7GIn3fjv56oFNk6c_CT_9L3vex9CHwk-J4TzC4qJuJCUSSL4OzQhUvBclgU-QBNMhcwxZfgIfYjxHmNCFVOH6IjKkquSlxN0dfO4hmyxyOau8T0MwZoumxlXQ8hWGwjwZx0gRojZ9WI5W33LptnPAJ3trTPhMZtvTDeawXp3gt63potwun-P0a8f85vZVb5cXS5m02VeM6WGPJmpQFSqYpQqzkkyTihlaWoZZQKaFigtDS9UUbEaWMOxZEUrKsEMCKiKY_R9p7seqx6aGtwQTKfXwfbJkPbG6v9_nL3Tt36jORNpA00Cn_cCwT-MEAfd21hD1xkHfoyaKMIkK4UsEnr2Cr33Y3Apnk5Xx1JQJfELdWs60Na1Pu2tt6J6ynk6eorAE_V1R9XBxxigfbZMsN4WuZUUel9kwj_9G_MZfmouAV92wJ11jflt3ygHiYHWvNCEU17Q4i-E9KxV</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2010872980</pqid></control><display><type>article</type><title>Type II Endometrial Cancer Overexpresses NILCO: A Preliminary Evaluation</title><source>Wiley Open Access</source><creator>Gonzalez-Perez, Ruben Rene ; Pattillo, Roland ; Candelaria, Pierre V. ; Lee, Regina ; Lanier, Viola ; Vann, Kiara T. ; Oprea-Ilies, Gabriela ; Daley-Brown, Danielle ; Quarshie, Alexander</creator><contributor>Singer, Eric A. ; Eric A Singer</contributor><creatorcontrib>Gonzalez-Perez, Ruben Rene ; Pattillo, Roland ; Candelaria, Pierre V. ; Lee, Regina ; Lanier, Viola ; Vann, Kiara T. ; Oprea-Ilies, Gabriela ; Daley-Brown, Danielle ; Quarshie, Alexander ; Singer, Eric A. ; Eric A Singer</creatorcontrib><description>Objective. The expression of NILCO molecules (Notch, IL-1, and leptin crosstalk outcome) and the association with obesity were investigated in types I and II endometrial cancer (EmCa). Additionally, the involvement of NILCO in leptin-induced invasiveness of EmCa cells was investigated. Methods. The expression of NILCO mRNAs and proteins were analyzed in EmCa from African-American n=29 and Chinese patients (tissue array, n=120 cases). The role of NILCO in leptin-induced invasion of Ishikawa and An3ca EmCa cells was investigated using Notch, IL-1, and leptin signaling inhibitors. Results. NILCO molecules were expressed higher in type II EmCa, regardless of ethnic background or obesity status of patients. NILCO proteins were mainly localized in the cellular membrane and cytoplasm of type II EmCa. Additionally, EmCa from obese African-American patients showed higher levels of NILCO molecules than EmCa from lean patients. Notably, leptin-induced EmCa cell invasion was abrogated by NILCO inhibitors. Conclusion. Type II EmCa expressed higher NILCO molecules, which may suggest it is involved in the progression of the more aggressive EmCa phenotype. Obesity was associated with higher expression of NILCO molecules in EmCa. Leptin-induced cell invasion was dependent on NILCO. Hence, NILCO might be involved in tumor progression and could represent a new target/biomarker for type II EmCa.</description><identifier>ISSN: 0278-0240</identifier><identifier>ISSN: 1875-8630</identifier><identifier>EISSN: 1875-8630</identifier><identifier>DOI: 10.1155/2017/8248175</identifier><identifier>PMID: 28659656</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Adenocarcinoma, Papillary - complications ; Adenocarcinoma, Papillary - diagnosis ; Adenocarcinoma, Papillary - ethnology ; Adenocarcinoma, Papillary - genetics ; Aged ; Antibodies - pharmacology ; Asian People ; Biological markers ; Biomarkers ; Black or African American ; Black People ; Cancer ; Carcinoma, Endometrioid - complications ; Carcinoma, Endometrioid - diagnosis ; Carcinoma, Endometrioid - ethnology ; Carcinoma, Endometrioid - genetics ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Crosstalk ; Cystadenocarcinoma, Serous - complications ; Cystadenocarcinoma, Serous - diagnosis ; Cystadenocarcinoma, Serous - ethnology ; Cystadenocarcinoma, Serous - genetics ; Cytoplasm ; Development and progression ; Diamines - pharmacology ; Disease Progression ; Endometrial cancer ; Endometrial Neoplasms - complications ; Endometrial Neoplasms - diagnosis ; Endometrial Neoplasms - ethnology ; Endometrial Neoplasms - genetics ; Endometrium ; Endometrium - metabolism ; Endometrium - pathology ; Female ; Gene expression ; Gene Expression Regulation, Neoplastic ; Genetic aspects ; Humans ; Inhibitors ; Interleukin 1 ; Interleukin-1 - antagonists &amp; inhibitors ; Interleukin-1 - genetics ; Interleukin-1 - metabolism ; Invasiveness ; Leptin ; Leptin - genetics ; Leptin - metabolism ; Middle Aged ; Neoplasm Staging ; Obesity ; Obesity - complications ; Obesity - diagnosis ; Obesity - ethnology ; Obesity - genetics ; Patients ; Phenotypes ; Protein Isoforms - antagonists &amp; inhibitors ; Protein Isoforms - genetics ; Protein Isoforms - metabolism ; Proteins ; Receptor, Notch1 - antagonists &amp; inhibitors ; Receptor, Notch1 - genetics ; Receptor, Notch1 - metabolism ; Signal Transduction ; Signaling ; Thiazoles - pharmacology</subject><ispartof>Disease markers, 2017-01, Vol.2017 (2017), p.1-14</ispartof><rights>Copyright © 2017 Danielle Daley-Brown et al.</rights><rights>COPYRIGHT 2017 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2017 Danielle Daley-Brown et al.; This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2017 Danielle Daley-Brown et al. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-240be7b9b42295518241224551f4247edfe226a5393b4ce4d50843f7b74ae7eb3</citedby><cites>FETCH-LOGICAL-c499t-240be7b9b42295518241224551f4247edfe226a5393b4ce4d50843f7b74ae7eb3</cites><orcidid>0000-0001-8922-6011 ; 0000-0002-2542-0111 ; 0000-0002-0096-8391 ; 0000-0001-9197-7172 ; 0000-0003-3447-5525</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28659656$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Singer, Eric A.</contributor><contributor>Eric A Singer</contributor><creatorcontrib>Gonzalez-Perez, Ruben Rene</creatorcontrib><creatorcontrib>Pattillo, Roland</creatorcontrib><creatorcontrib>Candelaria, Pierre V.</creatorcontrib><creatorcontrib>Lee, Regina</creatorcontrib><creatorcontrib>Lanier, Viola</creatorcontrib><creatorcontrib>Vann, Kiara T.</creatorcontrib><creatorcontrib>Oprea-Ilies, Gabriela</creatorcontrib><creatorcontrib>Daley-Brown, Danielle</creatorcontrib><creatorcontrib>Quarshie, Alexander</creatorcontrib><title>Type II Endometrial Cancer Overexpresses NILCO: A Preliminary Evaluation</title><title>Disease markers</title><addtitle>Dis Markers</addtitle><description>Objective. The expression of NILCO molecules (Notch, IL-1, and leptin crosstalk outcome) and the association with obesity were investigated in types I and II endometrial cancer (EmCa). Additionally, the involvement of NILCO in leptin-induced invasiveness of EmCa cells was investigated. Methods. The expression of NILCO mRNAs and proteins were analyzed in EmCa from African-American n=29 and Chinese patients (tissue array, n=120 cases). The role of NILCO in leptin-induced invasion of Ishikawa and An3ca EmCa cells was investigated using Notch, IL-1, and leptin signaling inhibitors. Results. NILCO molecules were expressed higher in type II EmCa, regardless of ethnic background or obesity status of patients. NILCO proteins were mainly localized in the cellular membrane and cytoplasm of type II EmCa. Additionally, EmCa from obese African-American patients showed higher levels of NILCO molecules than EmCa from lean patients. Notably, leptin-induced EmCa cell invasion was abrogated by NILCO inhibitors. Conclusion. Type II EmCa expressed higher NILCO molecules, which may suggest it is involved in the progression of the more aggressive EmCa phenotype. Obesity was associated with higher expression of NILCO molecules in EmCa. Leptin-induced cell invasion was dependent on NILCO. Hence, NILCO might be involved in tumor progression and could represent a new target/biomarker for type II EmCa.</description><subject>Adenocarcinoma, Papillary - complications</subject><subject>Adenocarcinoma, Papillary - diagnosis</subject><subject>Adenocarcinoma, Papillary - ethnology</subject><subject>Adenocarcinoma, Papillary - genetics</subject><subject>Aged</subject><subject>Antibodies - pharmacology</subject><subject>Asian People</subject><subject>Biological markers</subject><subject>Biomarkers</subject><subject>Black or African American</subject><subject>Black People</subject><subject>Cancer</subject><subject>Carcinoma, Endometrioid - complications</subject><subject>Carcinoma, Endometrioid - diagnosis</subject><subject>Carcinoma, Endometrioid - ethnology</subject><subject>Carcinoma, Endometrioid - genetics</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Crosstalk</subject><subject>Cystadenocarcinoma, Serous - complications</subject><subject>Cystadenocarcinoma, Serous - diagnosis</subject><subject>Cystadenocarcinoma, Serous - ethnology</subject><subject>Cystadenocarcinoma, Serous - genetics</subject><subject>Cytoplasm</subject><subject>Development and progression</subject><subject>Diamines - pharmacology</subject><subject>Disease Progression</subject><subject>Endometrial cancer</subject><subject>Endometrial Neoplasms - complications</subject><subject>Endometrial Neoplasms - diagnosis</subject><subject>Endometrial Neoplasms - ethnology</subject><subject>Endometrial Neoplasms - genetics</subject><subject>Endometrium</subject><subject>Endometrium - metabolism</subject><subject>Endometrium - pathology</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Genetic aspects</subject><subject>Humans</subject><subject>Inhibitors</subject><subject>Interleukin 1</subject><subject>Interleukin-1 - antagonists &amp; inhibitors</subject><subject>Interleukin-1 - genetics</subject><subject>Interleukin-1 - metabolism</subject><subject>Invasiveness</subject><subject>Leptin</subject><subject>Leptin - genetics</subject><subject>Leptin - metabolism</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Obesity - diagnosis</subject><subject>Obesity - ethnology</subject><subject>Obesity - genetics</subject><subject>Patients</subject><subject>Phenotypes</subject><subject>Protein Isoforms - antagonists &amp; inhibitors</subject><subject>Protein Isoforms - genetics</subject><subject>Protein Isoforms - metabolism</subject><subject>Proteins</subject><subject>Receptor, Notch1 - antagonists &amp; inhibitors</subject><subject>Receptor, Notch1 - genetics</subject><subject>Receptor, Notch1 - metabolism</subject><subject>Signal Transduction</subject><subject>Signaling</subject><subject>Thiazoles - pharmacology</subject><issn>0278-0240</issn><issn>1875-8630</issn><issn>1875-8630</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqNkcFP2zAUxq2JCTrgtvMUicukLWA7dmzvMKmqOqhU0R3Y2XKSFzBK7GIn3fjv56oFNk6c_CT_9L3vex9CHwk-J4TzC4qJuJCUSSL4OzQhUvBclgU-QBNMhcwxZfgIfYjxHmNCFVOH6IjKkquSlxN0dfO4hmyxyOau8T0MwZoumxlXQ8hWGwjwZx0gRojZ9WI5W33LptnPAJ3trTPhMZtvTDeawXp3gt63potwun-P0a8f85vZVb5cXS5m02VeM6WGPJmpQFSqYpQqzkkyTihlaWoZZQKaFigtDS9UUbEaWMOxZEUrKsEMCKiKY_R9p7seqx6aGtwQTKfXwfbJkPbG6v9_nL3Tt36jORNpA00Cn_cCwT-MEAfd21hD1xkHfoyaKMIkK4UsEnr2Cr33Y3Apnk5Xx1JQJfELdWs60Na1Pu2tt6J6ynk6eorAE_V1R9XBxxigfbZMsN4WuZUUel9kwj_9G_MZfmouAV92wJ11jflt3ygHiYHWvNCEU17Q4i-E9KxV</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Gonzalez-Perez, Ruben Rene</creator><creator>Pattillo, Roland</creator><creator>Candelaria, Pierre V.</creator><creator>Lee, Regina</creator><creator>Lanier, Viola</creator><creator>Vann, Kiara T.</creator><creator>Oprea-Ilies, Gabriela</creator><creator>Daley-Brown, Danielle</creator><creator>Quarshie, Alexander</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7TK</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8922-6011</orcidid><orcidid>https://orcid.org/0000-0002-2542-0111</orcidid><orcidid>https://orcid.org/0000-0002-0096-8391</orcidid><orcidid>https://orcid.org/0000-0001-9197-7172</orcidid><orcidid>https://orcid.org/0000-0003-3447-5525</orcidid></search><sort><creationdate>20170101</creationdate><title>Type II Endometrial Cancer Overexpresses NILCO: A Preliminary Evaluation</title><author>Gonzalez-Perez, Ruben Rene ; Pattillo, Roland ; Candelaria, Pierre V. ; Lee, Regina ; Lanier, Viola ; Vann, Kiara T. ; Oprea-Ilies, Gabriela ; Daley-Brown, Danielle ; Quarshie, Alexander</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-240be7b9b42295518241224551f4247edfe226a5393b4ce4d50843f7b74ae7eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adenocarcinoma, Papillary - complications</topic><topic>Adenocarcinoma, Papillary - diagnosis</topic><topic>Adenocarcinoma, Papillary - ethnology</topic><topic>Adenocarcinoma, Papillary - genetics</topic><topic>Aged</topic><topic>Antibodies - pharmacology</topic><topic>Asian People</topic><topic>Biological markers</topic><topic>Biomarkers</topic><topic>Black or African American</topic><topic>Black People</topic><topic>Cancer</topic><topic>Carcinoma, Endometrioid - complications</topic><topic>Carcinoma, Endometrioid - diagnosis</topic><topic>Carcinoma, Endometrioid - ethnology</topic><topic>Carcinoma, Endometrioid - genetics</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Crosstalk</topic><topic>Cystadenocarcinoma, Serous - complications</topic><topic>Cystadenocarcinoma, Serous - diagnosis</topic><topic>Cystadenocarcinoma, Serous - ethnology</topic><topic>Cystadenocarcinoma, Serous - genetics</topic><topic>Cytoplasm</topic><topic>Development and progression</topic><topic>Diamines - pharmacology</topic><topic>Disease Progression</topic><topic>Endometrial cancer</topic><topic>Endometrial Neoplasms - complications</topic><topic>Endometrial Neoplasms - diagnosis</topic><topic>Endometrial Neoplasms - ethnology</topic><topic>Endometrial Neoplasms - genetics</topic><topic>Endometrium</topic><topic>Endometrium - metabolism</topic><topic>Endometrium - pathology</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Genetic aspects</topic><topic>Humans</topic><topic>Inhibitors</topic><topic>Interleukin 1</topic><topic>Interleukin-1 - antagonists &amp; inhibitors</topic><topic>Interleukin-1 - genetics</topic><topic>Interleukin-1 - metabolism</topic><topic>Invasiveness</topic><topic>Leptin</topic><topic>Leptin - genetics</topic><topic>Leptin - metabolism</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Obesity - diagnosis</topic><topic>Obesity - ethnology</topic><topic>Obesity - genetics</topic><topic>Patients</topic><topic>Phenotypes</topic><topic>Protein Isoforms - antagonists &amp; inhibitors</topic><topic>Protein Isoforms - genetics</topic><topic>Protein Isoforms - metabolism</topic><topic>Proteins</topic><topic>Receptor, Notch1 - antagonists &amp; inhibitors</topic><topic>Receptor, Notch1 - genetics</topic><topic>Receptor, Notch1 - metabolism</topic><topic>Signal Transduction</topic><topic>Signaling</topic><topic>Thiazoles - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gonzalez-Perez, Ruben Rene</creatorcontrib><creatorcontrib>Pattillo, Roland</creatorcontrib><creatorcontrib>Candelaria, Pierre V.</creatorcontrib><creatorcontrib>Lee, Regina</creatorcontrib><creatorcontrib>Lanier, Viola</creatorcontrib><creatorcontrib>Vann, Kiara T.</creatorcontrib><creatorcontrib>Oprea-Ilies, Gabriela</creatorcontrib><creatorcontrib>Daley-Brown, Danielle</creatorcontrib><creatorcontrib>Quarshie, Alexander</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Disease markers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gonzalez-Perez, Ruben Rene</au><au>Pattillo, Roland</au><au>Candelaria, Pierre V.</au><au>Lee, Regina</au><au>Lanier, Viola</au><au>Vann, Kiara T.</au><au>Oprea-Ilies, Gabriela</au><au>Daley-Brown, Danielle</au><au>Quarshie, Alexander</au><au>Singer, Eric A.</au><au>Eric A Singer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Type II Endometrial Cancer Overexpresses NILCO: A Preliminary Evaluation</atitle><jtitle>Disease markers</jtitle><addtitle>Dis Markers</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>2017</volume><issue>2017</issue><spage>1</spage><epage>14</epage><pages>1-14</pages><issn>0278-0240</issn><issn>1875-8630</issn><eissn>1875-8630</eissn><abstract>Objective. The expression of NILCO molecules (Notch, IL-1, and leptin crosstalk outcome) and the association with obesity were investigated in types I and II endometrial cancer (EmCa). Additionally, the involvement of NILCO in leptin-induced invasiveness of EmCa cells was investigated. Methods. The expression of NILCO mRNAs and proteins were analyzed in EmCa from African-American n=29 and Chinese patients (tissue array, n=120 cases). The role of NILCO in leptin-induced invasion of Ishikawa and An3ca EmCa cells was investigated using Notch, IL-1, and leptin signaling inhibitors. Results. NILCO molecules were expressed higher in type II EmCa, regardless of ethnic background or obesity status of patients. NILCO proteins were mainly localized in the cellular membrane and cytoplasm of type II EmCa. Additionally, EmCa from obese African-American patients showed higher levels of NILCO molecules than EmCa from lean patients. Notably, leptin-induced EmCa cell invasion was abrogated by NILCO inhibitors. Conclusion. Type II EmCa expressed higher NILCO molecules, which may suggest it is involved in the progression of the more aggressive EmCa phenotype. Obesity was associated with higher expression of NILCO molecules in EmCa. Leptin-induced cell invasion was dependent on NILCO. Hence, NILCO might be involved in tumor progression and could represent a new target/biomarker for type II EmCa.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>28659656</pmid><doi>10.1155/2017/8248175</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-8922-6011</orcidid><orcidid>https://orcid.org/0000-0002-2542-0111</orcidid><orcidid>https://orcid.org/0000-0002-0096-8391</orcidid><orcidid>https://orcid.org/0000-0001-9197-7172</orcidid><orcidid>https://orcid.org/0000-0003-3447-5525</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0278-0240
ispartof Disease markers, 2017-01, Vol.2017 (2017), p.1-14
issn 0278-0240
1875-8630
1875-8630
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5474242
source Wiley Open Access
subjects Adenocarcinoma, Papillary - complications
Adenocarcinoma, Papillary - diagnosis
Adenocarcinoma, Papillary - ethnology
Adenocarcinoma, Papillary - genetics
Aged
Antibodies - pharmacology
Asian People
Biological markers
Biomarkers
Black or African American
Black People
Cancer
Carcinoma, Endometrioid - complications
Carcinoma, Endometrioid - diagnosis
Carcinoma, Endometrioid - ethnology
Carcinoma, Endometrioid - genetics
Cell Line, Tumor
Cell Proliferation - drug effects
Crosstalk
Cystadenocarcinoma, Serous - complications
Cystadenocarcinoma, Serous - diagnosis
Cystadenocarcinoma, Serous - ethnology
Cystadenocarcinoma, Serous - genetics
Cytoplasm
Development and progression
Diamines - pharmacology
Disease Progression
Endometrial cancer
Endometrial Neoplasms - complications
Endometrial Neoplasms - diagnosis
Endometrial Neoplasms - ethnology
Endometrial Neoplasms - genetics
Endometrium
Endometrium - metabolism
Endometrium - pathology
Female
Gene expression
Gene Expression Regulation, Neoplastic
Genetic aspects
Humans
Inhibitors
Interleukin 1
Interleukin-1 - antagonists & inhibitors
Interleukin-1 - genetics
Interleukin-1 - metabolism
Invasiveness
Leptin
Leptin - genetics
Leptin - metabolism
Middle Aged
Neoplasm Staging
Obesity
Obesity - complications
Obesity - diagnosis
Obesity - ethnology
Obesity - genetics
Patients
Phenotypes
Protein Isoforms - antagonists & inhibitors
Protein Isoforms - genetics
Protein Isoforms - metabolism
Proteins
Receptor, Notch1 - antagonists & inhibitors
Receptor, Notch1 - genetics
Receptor, Notch1 - metabolism
Signal Transduction
Signaling
Thiazoles - pharmacology
title Type II Endometrial Cancer Overexpresses NILCO: A Preliminary Evaluation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T00%3A37%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Type%20II%20Endometrial%20Cancer%20Overexpresses%20NILCO:%20A%20Preliminary%20Evaluation&rft.jtitle=Disease%20markers&rft.au=Gonzalez-Perez,%20Ruben%20Rene&rft.date=2017-01-01&rft.volume=2017&rft.issue=2017&rft.spage=1&rft.epage=14&rft.pages=1-14&rft.issn=0278-0240&rft.eissn=1875-8630&rft_id=info:doi/10.1155/2017/8248175&rft_dat=%3Cgale_pubme%3EA550015085%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c499t-240be7b9b42295518241224551f4247edfe226a5393b4ce4d50843f7b74ae7eb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2010872980&rft_id=info:pmid/28659656&rft_galeid=A550015085&rfr_iscdi=true